RBC Capital Maintains Outperform on Nurix Therapeutics, Lowers Price Target to $26
Portfolio Pulse from Benzinga Newsdesk
RBC Capital analyst Gregory Renza maintains an Outperform rating on Nurix Therapeutics (NASDAQ:NRIX) but lowers the price target from $27 to $26.
October 14, 2024 | 1:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
RBC Capital maintains an Outperform rating on Nurix Therapeutics but lowers the price target from $27 to $26, indicating a slight adjustment in expectations.
The Outperform rating suggests continued confidence in NRIX's potential, but the slight reduction in price target indicates a minor adjustment in expectations. This may not significantly impact the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100